Sales & Earnings In Brief
GSK on consumer division profitability: "Some of you would like us to sell" the GlaxoSmithKline Consumer Healthcare business, CEO J.P. Garnier said to analysts during a year-end earnings call for the firm Feb. 8. "Remember, if we sell it as a standalone, the consumer healthcare profit margin will drop like lead, because we will lose all the synergies that exist," he commented. "It's artificially very, very profitable .... the value of the enterprise as a standalone in my view is less than incorporating to the group, jut simply on the cost synergies." Garnier also pointed to the "benefits of Rx product switching and being passed on and being prolonged by our consumer healthcare enterprise." Sales for the consumer unit increased 9% in the fourth quarter to $1.62 bil. (£= $1.97) and 6% for the full year to $6.09 bil. OTC medicine sales grew 5% for the full year over 2005, while Oral Care saw a 6% sales increase to $1.29 bil...
Learn what's happening at the US FDA. On the go.
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
